{"id":"W1977983810","doi":"10.1016/s0960-9776(11)70295-8","title":"Reappraising antiangiogenic therapy for breast cancer","year":2011,"lang":"en","type":"review","venue":"The Breast","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; National Health Research Institutes; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; National Institute for Health and Care Research; Canada Research Chairs; GlaxoSmithKline; Pfizer Canada; Cancer Research Institute","keywords":"Medicine; Bevacizumab; Sunitinib; Breast cancer; Oncology; Chemotherapy; Metastatic breast cancer; Internal medicine; Cancer; Angiogenesis; Trastuzumab; Clinical trial; Pharmacology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00250891,0.0005382008,0.0005899525,0.0007873751,0.0002428009,0.001671137,0.0006922599,0.001687289,0.00427305],"category_scores_gemma":[0.001543101,0.0001553111,0.0004779805,0.0006041307,0.0007915956,0.002095024,0.0007720922,0.002851201,0.001939653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008046596,"about_ca_system_score_gemma":0.001279178,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004915536,"about_ca_topic_score_gemma":0.001188141,"domain_scores_codex":[0.9992003,0.0002653508,0.00006471865,0.000115615,0.0002503105,0.0001038864],"domain_scores_gemma":[0.998903,0.0003166289,0.000132632,0.00007983475,0.0004061352,0.0001616952],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005303102,0.0003728012,0.0004457945,0.003004209,0.00006319751,0.0004950121,0.0002133115,0.0005654986,0.03316443,0.01513822,0.05107506,0.894932],"study_design_scores_gemma":[0.0001860139,0.001355829,0.001192697,0.0009157432,0.0001078307,0.00110615,0.0001310248,0.0005444697,0.009533292,0.005875876,0.9790252,0.00002592046],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01024643,0.925752,0.007646596,0.03329611,0.007361768,0.0001414796,0.0001244821,0.000173455,0.0152577],"genre_scores_gemma":[0.06394769,0.8654618,0.01297691,0.0269379,0.01022279,0.0001540028,0.0003826134,0.00009909006,0.01981713],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00427305,"threshold_uncertainty_score":0.0142948,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05578876287634275,"score_gpt":0.3466847822153159,"score_spread":0.2908960193389731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}